Merck Drug Shows First Survival Gain In Advanced Endometrial Cancer
On May 18, 2026, Merck said its drug sacituzumab tirumotecan improved overall survival in a Phase 3 trial of advanced or recurrent endometrial cancer, a first in this post-platinum immunotherapy setting.[1]
The 776-patient TroFuse-005 trial showed statistically significant gains in overall survival and progression-free survival versus physician's-choice chemotherapy, Merck said.[1] Patients received sac-TMT as an IV infusion every two weeks, Merck reported.[1] Merck said response-rate benchmarks were met and that side effects were similar to earlier trials, but it did not disclose detailed numerical outcomes and said full data will be presented at a medical conference.[1]
Sacituzumab tirumotecan is an antibody-drug conjugate and, if confirmed by the full data, could change options for patients whose cancers progressed after platinum chemotherapy and immunotherapy.[1]
Show source details & analysis (1 source)
📌 Key Facts
- On May 18, 2026, Merck announced Phase 3 results for sacituzumab tirumotecan (sac-TMT) in advanced or recurrent endometrial cancer.
- The 776-patient TroFuse-005 trial found statistically significant improvements in overall survival and progression-free survival versus physician’s-choice chemotherapy.
- Sacituzumab tirumotecan is the first antibody-drug conjugate to show a survival benefit for endometrial cancer in this post–platinum and immunotherapy setting.
- Patients received sac-TMT as an IV infusion every two weeks, and Merck reported response-rate benchmarks were met with side effects similar to earlier trials.
- Detailed numerical outcomes were not disclosed; investigators intend to present full Phase 3 data at a future medical conference.
📰 Source Timeline (1)
Follow how coverage of this story developed over time